Zacks Research Upgrades Kiniksa Pharmaceuticals International (NASDAQ:KNSA) to “Hold”

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Several other equities analysts have also commented on KNSA. Wedbush increased their price objective on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “outperform” rating in a research report on Wednesday. Canaccord Genuity Group began coverage on Kiniksa Pharmaceuticals International in a research note on Thursday, February 19th. They issued a “buy” rating and a $62.00 target price for the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, January 22nd. Wells Fargo & Company raised their price objective on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, The Goldman Sachs Group upped their target price on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $55.29.

Kiniksa Pharmaceuticals International Price Performance

Kiniksa Pharmaceuticals International stock opened at $43.49 on Wednesday. Kiniksa Pharmaceuticals International has a 1-year low of $18.25 and a 1-year high of $49.12. The business has a fifty day moving average price of $42.93 and a 200-day moving average price of $39.69. The stock has a market capitalization of $3.30 billion, a price-to-earnings ratio of 58.77 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, February 24th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.12). The business had revenue of $202.13 million during the quarter, compared to analysts’ expectations of $200.86 million. Kiniksa Pharmaceuticals International had a net margin of 8.71% and a return on equity of 11.48%. The company’s quarterly revenue was up 65.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.12) earnings per share. On average, equities research analysts anticipate that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current fiscal year.

Insider Activity

In related news, COO Eben Tessari sold 12,048 shares of the company’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $41.56, for a total value of $500,714.88. Following the completion of the transaction, the chief operating officer owned 16,666 shares of the company’s stock, valued at approximately $692,638.96. This represents a 41.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Barry D. Quart sold 20,129 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, December 15th. The shares were sold at an average price of $41.51, for a total transaction of $835,554.79. Following the completion of the sale, the director directly owned 12,546 shares in the company, valued at $520,784.46. This represents a 61.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 123,623 shares of company stock valued at $5,236,389 in the last three months. 53.48% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Rubric Capital Management LP lifted its stake in shares of Kiniksa Pharmaceuticals International by 2.3% in the 3rd quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock valued at $155,320,000 after purchasing an additional 90,194 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Kiniksa Pharmaceuticals International by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company’s stock valued at $128,409,000 after acquiring an additional 49,802 shares during the last quarter. Acadian Asset Management LLC increased its position in shares of Kiniksa Pharmaceuticals International by 22.6% during the second quarter. Acadian Asset Management LLC now owns 1,267,989 shares of the company’s stock valued at $35,067,000 after acquiring an additional 233,668 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Kiniksa Pharmaceuticals International by 45.3% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock worth $41,481,000 after acquiring an additional 332,846 shares during the last quarter. Finally, Qube Research & Technologies Ltd boosted its position in shares of Kiniksa Pharmaceuticals International by 277.8% during the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after purchasing an additional 653,236 shares during the period. 53.95% of the stock is currently owned by institutional investors and hedge funds.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.